ALS drugs from Denali, Calico come up short, marking setback for Healey trial
Denali’s medicine and a similar one from Calico Life Sciences and AbbVie were not much different than a placebo, bringing the ...
STAT15h
Pharma’s big patent cliff, more obesity fundraising, and a failed ALS study
STAT reporters discuss why a looming patent cliff could lead to more pharmaceutical deal-making and a new obesity startup.
BioSpace6h
HEALEY ALS Trial Serves Up More Disappointment as Denali, AbbVie/Calico Fail
Misses from amyotrophic lateral sclerosis hopefuls Denali Therapeutics and partners AbbVie and Calico Life Sciences mark the ...
STAT2d
Google’s secretive anti-aging company Calico finally released data. Its drug failed
The company said Monday that fosigotifator failed to outperform placebo in slowing the neurodegenerative disease, but is ...
FierceBiotech3d
Rival AbbVie and Denali prospects flunk phase 2/3 ALS tests, denting hopes for shared mechanism
AbbVie, Calico and Denali Therapeutics’ hopes of treating amyotrophic lateral sclerosis (ALS) by targeting eIF2B have all ...
The Pharma Letter1d
Calico next to fail in ALS
Calico Life Sciences, a biotech founded by Alphabet and Arthur Levinson focused on the biology of aging and age-related ...
Crain's Chicago Business2d
AbbVie and rival's ALS drugs both disappoint in study
In studies by Massachusetts General Hospital, the AbbVie-Calico collaborative drug and Denali Therapeutics' own drug failed to meet endpoints for treating amyotrophic lateral sclerosis, more widely ...